Integrating folate receptor alpha (FRα) IHC testing in ovarian cancer today
FRα is now an actionable target. With the recent approval of a FRα-targeted therapy, there is now a clinical need for testing of this biomarker and integration into the testing pathway of ovarian cancer patients.
To learn more about FRα IHC testing, register for the Lab Talk, The Assessment of Folate Receptor alpha (FRa) Expression in Ovarian Cancer for Clinical Decision Making with Dr. Kevin Golden to be held on 14th December 2022 at 12pm (ET).
A recording of this session will be made available on DXRX post event
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology (ASCP) as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.
Speaker name: Dr. Kevin Golden, MD/PhD
Kevin Golden, MD/PhD, is currently the laboratory medical director for Mountainview Hospital in Las Vegas, NV, and an active participant in several research projects for Sonic Healthcare.Dr. Golden earned his PhD in neuroscience and medical degrees from the University in Miami Miller School of Medicine. His post-graduate training includes a residency in anatomic and clinical pathology and fellowships in surgical and gastrointestinal pathology at Brigham and Women's Hospital in Boston, MA.
Dr. Golden’s organizational interests are in development of new assays for prediction of behavior of malignant neoplasms and raising awareness for these new assays with relation to disease-specific diagnosis and prognosis.